Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK's Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion

Jul 07 2021

• By Jessica Merrill

Axel Hoos, CEO of Scorpion Therapeutics — Axel Hoos

Related Content

PD-1 Inhibitor Market Poised For A New Round Of Expansion: After GSK’s Jemperli Approval, US FDA Still Has Three Novel Candidates Under Review

Apr 24 2021

Post-Novartis, GSK Assures Immuno-Oncology R&D Running At Full Speed

May 02 2014

Scorpion Nabs $108m, Biopharma Veterans For Precision Oncology 2.0

Oct 26 2020

GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning

Aug 06 2020

Walmsley Takes On Oncology: Can GSK Become A Power Player?

Jan 16 2018

Walmsley Looks Safe For Now, But GSK Faces M&A Pressure

Jul 05 2021

Related Companies

GSK plc

Scorpion Therapeutics, Inc.

Bristol Myers Squibb Company

Novartis AG

Additional Topics

Leadership Companies StartUps and SMEs ImmunoOncology Executive Changes Cancer BioPharmaceutical

More from Leadership

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window